Skip to content
lifestyle.californiaconsumerbanking.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
NewcelX Ltd.
NewcelX Enters into Binding Term Sheet to Divest Legacy Mazindol Portfolio (CVR), Providing for Upfront Cash, Equity Ownership and Up to $55 Million in Potential Milestone Payments
November 4, 2026
NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes
September 28, 2026
NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing
July 31, 2026
NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio
July 15, 2026
NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board
July 8, 2026
NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
July 1, 2026